REPLライブシグナル | Getagraph.comで利益を最大化

買う 107824 min ago

@ $6.89

発行日: 15 2月 2024 @ 04:38

リターン: -2.47%

前回のシグナル: 2月 15 - 03:38

前回のシグナル: 売る

リターン: -2.96 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):

Stats
本日の出来高	108 140
平均出来高	1.23M
時価総額	412.53M
EPS	$0 ( 2024-02-08 )
次の収益日	( $-0.860 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.13
ATR14	$0.0150 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Peeples-dyer Veleka	Buy	32 000	Stock Option (right to buy)
2024-04-01	Patel Sushil	Buy	250 000	Employee Stock Option (right to buy)
2024-04-01	Patel Sushil	Buy	83 335	Common Stock
2024-04-01	Pucci Paolo	Buy	32 000	Stock Option (right to buy)
2024-04-01	Xynos Konstantinos	Buy	26 665	Common Stock

INSIDER POWER
74.49
Last 98 transactions
Buy: 2 588 053 \| Sell: 457 936

ボリューム相関

長: -0.56 (weak negative)

短: 0.60 (weak)

Signal:(65.469) Neutral

Replimune Group Inc 相関

10 最も正の相関
BNIXU	0.927
CASS	0.908
ATIF	0.895
COLL	0.894
COFS	0.893
CNXC	0.893
NIU	0.888
FCBP	0.887
DRTT	0.884
BTAI	0.882

10 最も負の相関
MTEK	-0.873
NGMS	-0.849
CRSA	-0.842
PPBT	-0.839
PLMR	-0.83
SLDP	-0.828
OSMT	-0.828
MVBF	-0.821
TCRX	-0.821
PMD	-0.819

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Replimune Group Inc 相関 - 通貨/商品

0.41
( neutral )

0.00
( neutral )

0.39
( neutral )

-0.61
( weak negative )

-0.55
( weak negative )

Replimune Group Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-2.45M (0.00 %)
EPS:	$-2.99

FY	2023
収益:	$0
総利益:	$-2.45M (0.00 %)
EPS:	$-2.99

FY	2022
収益:	$0
総利益:	$-4.58M (0.00 %)
EPS:	$-2.26

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.750

Financial Reports:

No articles found.

Replimune Group Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.